Luminex Corporation Begins Clinical Trials for ARIES™ GBS Assay
News Jun 09, 2015
Luminex Corporation has announced that it has commenced clinical and analytical studies to evaluate the company's ARIES™ Group B Streptococcus (GBS) Assay.
"We continue to build momentum in our commercial launch schedule for the ARIES platform with the start of clinical trials for GBS, the third assay in the ARIES pipeline," said Homi Shamir, President and CEO of Luminex. "The progression of our ARIES menu with assays that are important to patient care continues and the Group B Strep assay is a key contributor due to the high prevalence and potentially serious or life threatening consequences to newborns."
The clinical trials for the ARIES GBS Assay are being conducted at several clinical laboratories in the U.S., and Luminex still expects its FDA submission for the ARIES platform and ARIES HSV 1&2 Assay to occur in the summer of 2015.